CoChat

Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report

Open access
Garel, Nicolas, Greenway, Kyle T., Dinh-Williams, Lê-Anh L., Thibault-Levesque, Julien, Jutras-Aswad, Didier, Turecki, Gustavo, Rej, Soham, Richard-Devantoy, Stephane · 2023 · Neuropsychopharmacology

The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.

Abstract

We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none in patients actively suffering from TRD. In this ambi-directional cohort study, discontinuation of long-term (>6 month) BZDRs was attempted in 22 patients with severe unipolar or bipolar TRD receiving a course of six subanesthetic ketamine infusions over four weeks. We investigated the rates of successful BZDRs deprescription, trajectories of acute psychological withdrawal symptoms, and subsequent BZDRs abstinence during a mean follow-up of 1 year (primary outcome). Clinically significant deteriorations in depression, anxiety, sleep, and/or suicidality during the acute BZDR discontinuation phase were measured by repeated standardized scales and analyzed by latent growth curve models and percent correct classification analysis. Of the 22 eligible patients, all enrolled in this study and 91% (20/22) successfully discontinued all BZDRs by the end of the 4-week intervention, confirmed by urinary analyses. Less than 25% of discontinuers experienced any significant worsening of anxiety, depression, sleep difficulties, or suicidality during treatment. During follow-up (mean [range] duration, 12 [3–24] months), 64% (14/22) of patients remained abstinent from any BZDRs. These preliminary results suggest that ketamine infusions for TRD may facilitate the deprescription of BZDRs, even in patients with active depressive symptoms and significant comorbidity. Further investigation is warranted into this potential novel application of ketamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-023-01689-y

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Consort diagram.
Fig. 1 Consort diagram.CC BY · PubMed Central
Fig. 2 Unadjusted Kaplan–Meier estimates of BZDR restarting for successful discontinuers after the ketamine intervention. Kaplan–Meier survival curve showing time to restarting BZDRs, in weeks, with an estimated cumulative survival rate of 68% (95% CI: 0.51–0.91). The numbers below the Kaplan–Meier curves represent the numbers of patients followed up and the numbers censored at each timepoint.
Fig. 2 Unadjusted Kaplan–Meier estimates of BZDR restarting for successful discontinuers after the ketamine intervention. Kaplan–Meier survival curve showing time to restarting BZDRs, in weeks, with an estimated cumulative survival rate of 68% (95% CI: 0.51–0.91). The numbers below the Kaplan–Meier curves represent the numbers of patients followed up and the numbers censored at each timepoint.CC BY · PubMed Central
Fig. 3 Symptom trajectories during treatment and acute withdrawal. Illustration of raw clinical scores (Y axis) for (A) depression (BDI-II), (B) anxiety (STAI-A), (C) sleep (LSEQ), and (D) suicidality (SSI) over each ketamine treatment session (X axis) for each subgroup of treatment responses. The black line represents estimated changes in symptoms over time for each subgroup with the mean at each treatment session (triangular dot) and standard error of the mean (grey). Each subject’s raw clinical trajectory is displayed as colored lines. Individual patients grouped as deteriorated (any significant deterioration), improved (significant improvement without any significant deterioration), or no change (no significant deterioration or improvement). BDI-II Beck depression Inventory, STAI-A State-Trait-Anxiety-Inventory (State), LSEQ Leeds Sleep Evaluation Questionnaire, SSI Scale for suicide ideation (current).
Fig. 3 Symptom trajectories during treatment and acute withdrawal. Illustration of raw clinical scores (Y axis) for (A) depression (BDI-II), (B) anxiety (STAI-A), (C) sleep (LSEQ), and (D) suicidality (SSI) over each ketamine treatment session (X axis) for each subgroup of treatment responses. The black line represents estimated changes in symptoms over time for each subgroup with the mean at each treatment session (triangular dot) and standard error of the mean (grey). Each subject’s raw clinical trajectory is displayed as colored lines. Individual patients grouped as deteriorated (any significant deterioration), improved (significant improvement without any significant deterioration), or no change (no significant deterioration or improvement). BDI-II Beck depression Inventory, STAI-A State-Trait-Anxiety-Inventory (State), LSEQ Leeds Sleep Evaluation Questionnaire, SSI Scale for suicide ideation (current).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. Palo Alto, CA, USA: Consulting Psychologists Press; 1983.

Cited by

See all 15

Metadata

Authors
Garel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S.
Affiliations
  • McGill University (CA)
  • Jewish General Hospital (CA)
  • Douglas Mental Health University Institute (CA)
Corresponding author
Garel, Nicolas
Venue
Neuropsychopharmacology
Published
2023-08-02
Volume
48
Issue
12
Pages
1769-1777
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4385482916
Cited by
13
References
65
Citations by year
2026: 7 · 2025: 4 · 2024: 1 · 2023: 1
FWCI
2.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
ketamine, treatment-resistant depression, benzodiazepine withdrawal, long-term benzodiazepine use, bipolar depression, withdrawal symptoms, suicidality, anxiety
MeSH terms
Deprescriptions, Benzodiazepines, Depression, Humans, Infusions, Intravenous, Ketamine, Substance Withdrawal Syndrome, Cohort Studies, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. https://app.cochat.ai/papers/10.1038/s41386-023-01689-y
The paper
Garel, N., Greenway, K. T., Dinh-Williams, L.-A. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023). Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01689-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.